97 results
S-1
EX-3.1
AGIO
Agios Pharmaceuticals Inc
10 Jun 13
IPO registration
12:00am
) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares … Stock, (2) the holders of a majority of the outstanding shares of Series B Preferred Stock and (3) the holders of a majority of the outstanding shares
8-K
EX-3.1
AGIO
Agios Pharmaceuticals Inc
30 Jul 13
Unregistered Sales of Equity Securities
12:00am
of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective … of Preferred Stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority
S-1
EX-3.2
AGIO
Agios Pharmaceuticals Inc
10 Jun 13
IPO registration
12:00am
or these By-laws, the holders of a majority in voting power of the shares of the capital stock of the corporation issued and outstanding and entitled … by a class or classes or series of capital stock is required by law or the Certificate of Incorporation, the holders of a majority in voting power
S-8
EX-99.3
agsie63rudi6rht4 7ki
26 Sep 22
Registration of securities for employees
5:19pm
S-1
EX-4.2
ws3o57g
10 Jun 13
IPO registration
12:00am
S-3ASR
EX-4.6
y4hurk 2cy5o
30 Apr 20
Automatic shelf registration
4:19pm
8-K
EX-3.1
rj73naytt90x6k6c
19 Dec 18
Amendments to Articles of Incorporation or Bylaws
4:30pm
8-K
EX-3.2
69a6rfbz61qm3
30 Jul 13
Unregistered Sales of Equity Securities
12:00am
S-8
EX-99.2
jp0ibz xiqyx2
26 Sep 22
Registration of securities for employees
5:19pm
S-8
EX-99.1
04p8d
26 Sep 22
Registration of securities for employees
5:19pm
8-K
EX-99.1
d2lf70zefb4
19 Nov 14
Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120
12:00am
8-K
EX-99.1
by9e5
16 Jun 14
Other Events
12:00am
S-3ASR
EX-4.7
2zrrjcg
30 Apr 20
Automatic shelf registration
4:19pm
8-K
EX-99.1
2bn8m42b9ovsy4 el
8 Dec 14
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
12:00am
8-K
EX-99.1
rnbqihr2xor
13 Jan 14
Regulation FD Disclosure
12:00am
S-3ASR
14yc5x954pjj2
30 Apr 20
Automatic shelf registration
4:19pm